Immunovant's muscle disorder treatment meets main goal in late-stage trial
19/03/2025 11:52
March 19 (Reuters) - Immunovant IMVT.O said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Maju Samuel) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Immunovant
See all newsU.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Immunovant Q3 net loss smaller than expected
Brief: Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million